EHA 2017 | Is venetoclax highly efficacious in a subset of MM patients?
Shaji Kumar
• 22 Jun 2017
Shaji Kumar, MD, from the Mayo Clinic, Rochester, MN, USA, discusses the efficacy of inhibiting Bcl-2 signalling activity, namely through the novel drug, venetoclax, in the treatment of multiple myeloma (MM) patients carrying the t(11;14) translocation. Here, he explains that this subgroup of patients are particularly sensitive to Bcl-2 inhibition due to their cells carrying high levels of Bcl-2 and low levels of Mcl-1 and thus venetoclax is especially efficacious in treating this subgroup of patients, as evidenced in results from clinical trials (NCT01794520). This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
